BioCardia, Inc. (Nasdaq: BCDA) is a clinical-stage developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The Company has two biotherapeutic platforms, CardiAMP autologous bone marrow-derived mononuclear cell therapy for cardiovascular indications and the NK1R+ allogeneic bone marrow-derived mesenchymal stem cell therapies for cardiovascular and pulmonary diseases. These platforms underlie several clinical-stage product candidates, each with the potential to meaningfully benefit millions of patients.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth!
NoACC.23 Learning Pathways? (select all that apply)
Electrophysiology, Heart Failure and Cardiomyopathies, Interventional and Structural Cardiology, Ischemic Heart DiseaseFirst time Exhibitor?
Yes